Myriad Genetics (MYGN) Shares are Down -5.03%

On a relative basis, the stock has outperformed the S&P 500 by 0.2% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The 4-week change in the price of the stock is -0.34% and the stock has fallen -5.03% in the past 1 week.

The stock has recorded a 20-day Moving Average of 2.27% and the 50-Day Moving Average is 13.88%.The 200 Day SMA reached 38.07%


Myriad Genetics (NASDAQ:MYGN): The stock opened in the green at $20.88 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $21.05 and a low of $20.52 for the day. The stock did not find buyers even at the lows and closed at $20.58 recording a loss of -0.58%. 2,017,944 shares exchanged hands during the trading day. The stock had closed at $20.58 in the previous days trading.

Myriad Genetics (MYGN) : The consensus price target for Myriad Genetics (MYGN) is $24.6 for the short term with a standard deviation of $8.76. The most optimist securities analyst among the 10 who monitor the stock believes that the stock can reach $47, however, the pessimist price target for the company is $18.

Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. Myriad operates through two segments: diagnostics, which provides testing and collaborative development of testing that is designed to assess an individuals risk for developing disease later in life, identify a patients likelihood of responding to drug therapy and guide a patients dosing, or assess a patients risk of disease progression and disease recurrence, and other, which provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients. It offers diagnostic tests for various diseases, such as myRisk Hereditary Cancer test for hereditary cancers; myPlan Lung Cancer test for lung cancer; myPath Melanoma test for melanoma; Prolaris test for prostate cancer, and Vectra DA for rheumatoid arthritis.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.